Evidence map›Paper›PMID 42003827›Full record

ArticleJournal of surgical oncology2026

Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors.

Katherine Y Chen, Mark Antkowiak, Ashwyn K Sharma, Robert Mallory, Adam M Burgoyne, Paul T Fanta, Jason K Sicklick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katherine Y ChenUniversity of California San Diego School of Medicine, San Diego, California, USA.
Mark AntkowiakDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California, USA.
Ashwyn K SharmaDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California, USA.
Robert MalloryDepartment of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California, USA.
Adam M BurgoyneUniversity of California San Diego School of Medicine, San Diego, California, USA.
Paul T FantaUniversity of California San Diego School of Medicine, San Diego, California, USA.
Jason K SicklickUniversity of California San Diego School of Medicine, San Diego, California, USA.ORCID https://orcid.org/0000-0003-4403-0271

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial ConsortiumU01CA278470 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOHN Walter GLOD, Jason Keith Sicklick · 2024 to 2026
$1.8M
Prognostic and Therapeutic Roles of Voltage Gated Potassium Channels in Managing KIT Mutant Gastrointestinal Stromal Tumors (GIST)R01CA292590 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jason Keith Sicklick · 2025 to 2026
$1.3M
FDA HHS R01 FD006334GIST Research Fund #3661NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA292590NCI NIH HHS T32 CA121938NCI NIH HHS U01 CA278470NIH HHS CA023100NIH HHS CA121938NIH HHS CA278470NIH HHS CA292590NIH HHS FD006334NIH HHS P30NIH HHS R01NIH HHS T32NIH HHS U01
6 · The paper itself

Abstract

BACKGROUND AND

objectivesSuccinate dehydrogenase-deficient (SDH-deficient) gastrointestinal stromal tumors (GIST) are characterized by variable disease biology with poor responses to traditional tyrosine kinase inhibitors. The role of surgical intervention has been highly debated.

methodsWe performed a single-institution retrospective analysis of metastatic SDH-deficient GIST patients who underwent complete (CC-0) cytoreductive surgery (CRS) from 2017 to 2023. Pathologic-Peritoneal Cancer Index (P-PCI) and GIST Metastatectomy-Surgical Complexity Score (GM-SCS) were used to quantify complexity. Kaplan-Meier survival analysis compared time to progression on systemic therapy immediately before CRS (TTP-1L) and second to last line of systemic therapy before CRS (TTP-2L) versus time to recurrence (TTR) after CRS.

resultsNine patients met inclusion criteria. The median age at CRS was 29 years (range: 17-43). Median P-PCI was 13 (IQR: 10-15) and median GM-SCS was 19 (IQR: 16-28). Clavien-Dindo grade ≥ 3 complication rate was 33.3% (3/9) within 90-days postoperatively. Median TTP-1L was unreached and median TTP-2L was 3.4 months (95% CI: 2.5-unreached), as compared to TTR at 26.1 months (95% CI: 15.2-unreached) post CRS (p ≤ 0.0001).

conclusionsPatients who underwent CC-0 CRS achieved prolonged disease control versus prior systemic therapies, suggesting that CRS may be a management option for highly selected SDH-deficient GIST patients.

Indexed as

Cytoreduction Surgical ProceduresGastrointestinal NeoplasmsGastrointestinal Stromal TumorsSuccinate DehydrogenaseAdolescentAdultFemaleHumansMaleRetrospective StudiesSurvival RateYoung AdultSuccinate Dehydrogenasecytoreductiondebulkingepimutantgastrointestinal stromal tumor (GIST)SDHASDHBSDHCsuccinate dehydrogenase (SDH)

Identifiers

PMID42003827
PMCPMC13353120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.